Difficult to treat asthma at high altitude
- Conditions
- Difficult to treat asthmaPhenotypes of severe asthmaClinical featuresPathophysiologyHigh altitude treatmentMoeilijk te behandelen astmaFenotypen van ernstig astmaKlinische kenmerkenPathofysiologieHooggebergte behandeling
- Registration Number
- NL-OMON26574
- Lead Sponsor
- Vereniging Nederland Davos
- Brief Summary
Bel, E. H. 2004. Clinical phenotypes of asthma. Curr.Opin.Pulm.Med. 10:44-50. <br> - Rijssenbeek-Nouwens LH, Bron AO, Naves C, Weller F, Weersink EJ, and Bel EH. Persistent airflow limitation in severe asthma is not an irreversible phenomenon. Proceedings of the American Thoracic Society 3 (abstract issue), A580. 2006. <br> - Grootendorst, D. C., S. E. Dahlen, J. W. Van Den Bos, E. J. Duiverman, M. Veselic-Charvat, E. J. Vrijlandt, S. O'Sullivan, M. Kumlin, P. J. Sterk, and A. C. Roldaan. 2001. Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids. Clin.Exp.Allergy. 31:400-408.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 150
1. Age 18-80 year
2. Difficult to treat asthma, defined as uncontrolled asthma despite the chronic use of > 1600 mcg inhaled beclomethason equivalent plus longacting beta-2 agonists or oral steroids.
Exclusion for treatment in Davos:
1. Active cardio-vascular disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in Asthma-control (ACQ) and FEV1 and decrease in mean oral steroid maintenance dose.
- Secondary Outcome Measures
Name Time Method Improvement in Asthma related Quality of Life (AQLQ), rhinosinusitis score (RSOM-31) fatique score (CIS-Fatique), body mass index (BMI), residual volume as percentage of total lung capacity (RV/TLC), exhaled nitric oxide (FeNO), changes in levels of 25-hydroxyvitamin D and 1.25-(OH)2 vitamin D.